MBZUAI's Eduardo da Veiga Beltrame is developing machine learning tools for analyzing single-cell RNA sequencing data, which measures RNA in thousands of individual cells. Sequencing costs have decreased faster than Moore's Law, enabling large-scale data collection in biology. RNA sequencing provides insights into gene expression and cellular activity, crucial for personalized medicine. Why it matters: Advancements in single-cell RNA sequencing and ML analysis will accelerate personalized medicine by providing detailed insights into cellular mechanisms and disease pathways.
A talk discusses the challenges of single-cell data analysis, such as feature sparsity and the effects of rare cells. AI/ML strategies are uniquely positioned to model this data. ImYoo, a startup founded in 2021, is applying single-cell model architectures for unsupervised discovery of patient groupings and predicting sample-level phenotypical data in autoimmune disease. Why it matters: This highlights the growing application of AI/ML in analyzing single-cell data for population-scale human health studies, an area ripe for innovation and improvement in the Middle East's growing biotech sector.
Eduardo da Veiga Beltrame, bioinformatics lead at ImYoo (a Caltech spinout), presented on scalable methods for single-cell omics data analysis, including kallisto|bustools and scvi-tools. He highlighted their use in ImYoo's decentralized longitudinal study on Inflammatory Bowel Disease (IBD), where patients self-collect capillary blood samples. Beltrame also discussed his research on STEM education programs in Brazil as a visiting scholar at UC Berkeley. Why it matters: This highlights the growing trend of decentralized clinical studies leveraging advanced single-cell technologies for precision medicine, showcasing the potential of remote data collection and analysis in understanding complex diseases.
Eran Segal from Weizmann Institute of Science presented The Human Phenotype Project, a large-scale prospective cohort with over 10,000 participants. The project aims to identify novel molecular markers and develop prediction models for disease onset using deep profiling. The profiling includes medical history, lifestyle, blood tests, and molecular profiling of the transcriptome, genetics, microbiome, metabolome and immune system. Why it matters: Such projects demonstrate the growing focus on personalized medicine in the region, utilizing advanced AI and machine learning techniques for disease prevention and treatment.
Natasa Przulj at the Barcelona Supercomputing Center is developing an AI framework that fuses multi-omic data to improve precision medicine. The framework uses graph-regularized non-negative matrix tri-factorization (NMTF) and network science algorithms for patient stratification, biomarker prediction, and drug repurposing. It is applied to diseases like cancer, Covid-19, and Parkinson's. Why it matters: This research can enable more personalized and effective treatments by leveraging complex biological data to understand disease mechanisms and tailor therapies.